These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12942693)

  • 1. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Hamaguchi Y; Fujimoto M; Takehara K; Sato S
    Clin Exp Rheumatol; 2003; 21(4):429-36. PubMed ID: 12942693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
    Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
    Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis.
    Sato S; Nagaoka T; Hasegawa M; Nishijima C; Takehara K
    Dermatology; 2000; 200(3):196-201. PubMed ID: 10828626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis.
    Kumánovics G; Görbe E; Minier T; Simon D; Berki T; Czirják L
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-138-44. PubMed ID: 24773853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
    Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
    Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
    Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Usui A; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Aug; 36(8):1657-62. PubMed ID: 19531747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
    Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surfactant protein D (SP-D) and systemic scleroderma (SSc).
    Maeda M; Ichiki Y; Aoyama Y; Kitajima Y
    J Dermatol; 2001 Sep; 28(9):467-74. PubMed ID: 11603386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
    Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
    J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of the serum KL-6 assay in patients with hepatitis C virus.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2005; 48(6):400-4. PubMed ID: 16024944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis.
    Hasegawa M; Fujimoto M; Hamaguchi Y; Matsushita T; Inoue K; Sato S; Takehara K
    J Rheumatol; 2011 May; 38(5):877-84. PubMed ID: 21239758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis.
    Yokoyama A; Kondo K; Nakajima M; Matsushima T; Takahashi T; Nishimura M; Bando M; Sugiyama Y; Totani Y; Ishizaki T; Ichiyasu H; Suga M; Hamada H; Kohno N
    Respirology; 2006 Mar; 11(2):164-8. PubMed ID: 16548901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.
    Nakajima H; Harigai M; Hara M; Hakoda M; Tokuda H; Sakai F; Kamatani N; Kashiwazaki S
    J Rheumatol; 2000 May; 27(5):1164-70. PubMed ID: 10813282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.
    Satoh H; Kurishima K; Ishikawa H; Ohtsuka M
    J Intern Med; 2006 Nov; 260(5):429-34. PubMed ID: 17040248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.